leuprolide acetate for depot suspension

P2, N=19, Active, not recruiting, University of Colorado, Denver | Trial completion date: Apr 2024 --> Apr 2025

P3, N=392, Recruiting, NYU Langone Health

P3, N=2250, Active, not recruiting, Sumitomo Pharma Switzerland GmbH | Trial completion date: Feb 2027 --> Dec 2024 | Trial primary completion date: Feb 2027 --> Dec 2024

P2, N=60, Active, not recruiting, Xiao X. Wei, MD | Recruiting --> Active, not recruiting

P=N/A, N=1, Completed, Pfizer | Trial completion date: Jun 2023 --> Apr 2024 | Trial primary completion date: Jun 2023 --> Apr 2024

P3, N=3100, Suspended, Novartis Pharmaceuticals | Recruiting --> Suspended

P2, N=120, Not yet recruiting, Mayo Clinic

P=N/A, N=94, Recruiting, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Not yet recruiting --> Recruiting

P2, N=257, Completed, Palleos Healthcare GmbH | Active, not recruiting --> Completed

P=N/A, N=42, Active, not recruiting, Medical College of Wisconsin | N=60 --> 42

P2, N=37, Recruiting, Peking University First Hospital

Despite only including AR+ SDC of the parotid, immunoprofiles, such as expression of HER-2, were highly variable, highlighting the potential to tailor systemic regimens based on individual histologic profiles in the future. Studies with larger patient numbers using tumor-specific molecular profiling and tumor heterogeneity analyses are justified to better understand the biology of these tumors. Molecularly informed treatment approaches, including the potential use of AR- and HER-2/Neu-directed therapies upfront in the definitive setting, may hold future promise to further improve outcomes for these patients.

P2, N=0, Withdrawn, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | N=30 --> 0 | Not yet recruiting --> Withdrawn

Mice in the superovulation (PG) group were administered 7.5 IU of PMSG, followed by the injection of 3.5 μg of GnRHa (Leuprorelin) 48 h later, while mice in the control group (CTR) mated naturally...The transcriptome analysis showed that superphysiological estrogen led to a response of the uterus to a high estrogen signal, resulting in abnormal endometrium and extracellular matrix remodeling and up-regulation of ion transport and inflammation-related genes. Our findings suggest that a combination of PMSG and GnRHa trigger impaired embryo implantation in mice, as the excessive uterine response to superphysiological estrogen levels can lead to the change of gene expression related to endometrial remodeling, abnormal expression of uterine ion transport genes and excessive immune-related genes.

P2, N=88, Recruiting, Fudan University | N=66 --> 88

P1, N=30, Active, not recruiting, Colorado Center for Reproductive Medicine | Recruiting --> Active, not recruiting | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Sep 2023 --> Sep 2024

P3, N=3100, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting

P3, N=3100, Not yet recruiting, Novartis Pharmaceuticals | Trial primary completion date: Jul 2028 --> Sep 2029

P4, N=80, Recruiting, Takeda | Trial completion date: Apr 2024 --> May 2025 | Trial primary completion date: Jan 2024 --> May 2025

P2, N=202, Recruiting, Cancer Research Antwerp | Trial completion date: Sep 2022 --> Dec 2025 | Trial primary completion date: Dec 2021 --> Aug 2025

P2, N=31, Recruiting, H. Lee Moffitt Cancer Center and Research Institute | Phase classification: P2a --> P2 | Trial completion date: May 2026 --> Jan 2027 | Trial primary completion date: May 2025 --> Jan 2027

The panel reached a consensus on 18 statements based on recent evidence and expert insights. These consensus statements serve as a practical recommendation for clinicians in Hong Kong, and possibly the Asia-Pacific region, in the management of cardiometabolic toxicities of ADT or AR axis-targeted therapies in men with PCa.

P2, N=110, Recruiting, Dana-Farber Cancer Institute | Not yet recruiting --> Recruiting

P4, N=126, Completed, Children's Hospital of Fudan University | Recruiting --> Completed

P1, N=20, Completed, Medical University of South Carolina | Active, not recruiting --> Completed

P3, N=2250, Active, not recruiting, Myovant Sciences GmbH | Recruiting --> Active, not recruiting

P2, N=124, Not yet recruiting, National Taiwan University Hospital

In contrast to their male counterparts, female Nf1 mice have increased expression of glial interleukin-1β (IL-1β), which is neurotoxic to RGCs in vitro. Importantly, both IL-1β neutralization and leuprolide-mediated estrogen suppression decrease IL-1β expression and ameliorate RGC dysfunction, providing preclinical proof-of-concept evidence supporting novel neuroprotective strategies for NF1-OPG-induced vision loss.

P1, N=20, Recruiting, Johns Hopkins University | Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Mar 2024 --> Mar 2025

P2, N=82, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024

P2, N=32, Recruiting, Rana McKay, MD | Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Dec 2023 --> Dec 2025

P=N/A, N=163, Active, not recruiting, Stanford University

Despite all the advances in this field, there is yet no effective evidence-based regimen of ST, with all the clinical trials identified showing low rates of complete and partial responses. Further, translational studies are urgently required to characterize molecular targets and effective ST.

P2, N=110, Not yet recruiting, Dana-Farber Cancer Institute | Initiation date: Aug 2023 --> Jan 2024

P3, N=45, Completed, AbbVie | Active, not recruiting --> Completed

Clinical Trial Registration Number: NCT02319837 Sponsored by The study was sponsored by Pfizer Inc. In pts with high-risk BCR who suspended tx, the tx effect on MFS with enza mono was not different compared with leuprolide alone, though more pts reached tx suspension criteria with enza mono. However, in the no suspension group, enza mono prolonged MFS vs leuprolide alone, though the number of MFS events was limited (n=4). Pts with prior RP were also more likely to reach the PSA threshold for tx suspension.

P2, N=32, Recruiting, Rana McKay, MD

P3, N=224, Recruiting, Seoul National University Hospital | Trial completion date: Oct 2023 --> Dec 2024 | Trial primary completion date: Sep 2023 --> Dec 2024

P=N/A, N=72, Completed, University of Colorado, Denver | Recruiting --> Completed | Trial completion date: Aug 2023 --> May 2023 | Trial primary completion date: Aug 2023 --> May 2023

P3, N=61, Active, not recruiting, Alliance for Clinical Trials in Oncology | Suspended --> Active, not recruiting | N=1002 --> 61